Cover Image
Read Now

CADTH Canadian Drug Expert Committee recommendation: Guselkumab (Tremfya -- Janssen Inc.) indication : for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy

The CADTH Canadian Drug Expert Committee (CDEC) recommends that guselkumab be reimbursed for adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, with the following criteria and condition. Reimburse in a manner similar to other biologics fo...

Full description

Bibliographic Details
Corporate Authors: CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) CADTH February 21, 2018, 2018
Edition:Version 1.0
Series:CADTH common drug review
Subjects:
Insurance, Health, Reimbursement
Interleukin-23 Subunit P19 / Therapeutic Use
Canada
Antibodies, Monoclonal / Therapeutic Use
Interleukin-23 Subunit P19 / Economics
Drug Costs
Psoriasis / Drug Therapy
Antibodies, Monoclonal / Economics
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:The CADTH Canadian Drug Expert Committee (CDEC) recommends that guselkumab be reimbursed for adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, with the following criteria and condition. Reimburse in a manner similar to other biologics for the treatment of moderate-to-severe plaque psoriasis. Treatment should be discontinued if a response to treatment with guselkumab has not been demonstrated after 16 weeks
Item Description:"Final."
Physical Description:1 PDF file (9 pages)

Similar Items